Boston Scientific
As of the edition of 20 October 2026, Boston Scientific runs 3 drugs, 1 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 6 company names in this family.
- Apollo Endosurgery, Inc.: acquired in 2023; successor Boston Scientific Corporation
- Silk Road Medical: acquired in 2024; successor Boston Scientific Corporation
- Axonics, Inc.: acquired in 2024; successor Boston Scientific Corporation
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Polidocanol | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| PTGER4 Prostaglandin E2 receptor EP4 subtype | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Boston Scientific needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 1 trials led
- Digestive system: 1 trials led
- Nervous system: 1 trials led